Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Silberstein

Neurology Philadelphia, PA Medical Doctor

NPI 1881617413 CMS profile 312280

900 Walnut St, 2Nd Floor, Philadelphia, PA 19107

Open in the dashboard

General payments

$428,329

448 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$289,292 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stephen Silberstein of Philadelphia, PA is reported in the CMS Open Payments database as having received $428,329 across 448 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $289,292 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,300 6
2024 General $6,673 19
2023 General $25,131 56
2022 General $12,404 42
2021 General $48,895 34
2020 General $76,740 68
2019 General $246,187 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Silberstein
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephen Silberstein were reported at $12,300. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephen Silberstein Neurology median Middle half National median
2019 $246,187 $474 $118–$2,177 $163
2020 $76,740 $367 $82–$2,309 $114
2021 $48,895 $438 $104–$2,547 $132
2022 $12,404 $442 $103–$2,388 $149
2023 $25,131 $464 $119–$2,312 $160
2024 $6,673 $468 $119–$2,323 $164
2025 $12,300 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $120,870 50 payments
  2. Teva Pharmaceuticals USA, Inc. $77,133 66 payments
  3. Allergan Inc. $73,856 68 payments
  4. Lilly USA, LLC $59,297 79 payments
  5. Medical Device Business Services, Inc. $24,613 8 payments
  6. AbbVie, Inc. $16,936 53 payments
  7. Amgen Inc. $13,561 20 payments
  8. Biodelivery Sciences International, Inc. $8,911 10 payments
  9. Impel Pharmaceuticals Inc. $7,451 23 payments
  10. Lundbeck LLC $7,125 4 payments
  11. Other $18,577 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $283,412 67 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $95,610 43 payments
  3. Travel and Lodging $25,969 46 payments
  4. Honoraria $14,250 4 payments
  5. Food and Beverage $8,860 278 payments
  6. Education $188 9 payments
  7. Grant $42 1 payment
Products named General payments · program years 2019–2025
  1. TROKENDI XR $120,870 50 payments
  2. Ajovy Central Nervous System $57,563 41 payments
  3. EMGALITY $40,488 36 payments
  4. TRUFILL $24,613 8 payments
  5. AJOVY Central Nervous System $19,470 21 payments
  6. UBRELVY $18,788 26 payments
  7. BOTOX Anti-Migraine $17,225 3 payments
  8. AIMOVIG $13,299 32 payments
  9. BOTOX Neuroscience $9,839 8 payments
  10. BOTOX Neuroscience $9,131 6 payments
  11. Other $34,493 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record